

30 September 2016

Extension of Omniblend Innovation Tranche 2 Settlement Deadline

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on its portfolio company, Omniblend Innovation Pty Ltd, the medical technology company focused on foods for special medical purposes.

EVE and Omniblend Innovation have mutually extended the settlement of the tranche 2 investment to better align with Omniblend Innovation's cash flow requirements.

Under the revised terms, payment for tranche 2 will be made by no later than 30 November 2016.

-ENDS-

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in technology companies. With a preference for companies that have global scale, EVE is an investment partner that wants to help build ground breaking and enduring technology.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

About Omniblend Innovation

Omniblend Innovation is a private Melbourne based company developing evidence-based dietary interventions to improve the lives of people with common chronic diseases such type-2 diabetes and low blood pressure (hypotension).

In August 2016 the Company launched its maiden product, Faulding® GlucoControl™ for use in the dietary management of type 2 diabetes and pre-diabetes.

For more information, please visit www.obinnovation.com.au

For more information:

Bill Fry
Executive Director
+61 8 6465 5500
billf@eveinvestments.com.au